Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart.
No risks detected for ABMD from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$338.47|
|52 Week High||US$242.73|
|52 Week Low||US$387.40|
|1 Month Change||-5.60%|
|3 Month Change||8.04%|
|1 Year Change||23.73%|
|3 Year Change||-23.81%|
|5 Year Change||164.84%|
|Change since IPO||5,661.19%|
Recent News & Updates
Abiomed: Impella Will Continue To Drive Revenue Growth
Abiomed’s strong growth drivers and advanced product pipeline will boost its long-term revenue growth. The company’s Impella range of micro heart pumps will continue to see increasing adoption globally. Long-term investors can buy the company’s shares around the current price to maximize their gain.
Here's What To Make Of Abiomed's (NASDAQ:ABMD) Decelerating Rates Of Return
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect...
|ABMD||US Medical Equipment||US Market|
Return vs Industry: ABMD underperformed the US Medical Equipment industry which returned 36.8% over the past year.
Return vs Market: ABMD underperformed the US Market which returned 35.3% over the past year.
Stable Share Price: ABMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ABMD's weekly volatility (4%) has been stable over the past year.
About the Company
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite.
Abiomed Fundamentals Summary
|ABMD fundamental statistics|
Is ABMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ABMD income statement (TTM)|
|Cost of Revenue||US$171.11m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||3.40|
|Net Profit Margin||16.51%|
How did ABMD perform over the long term?See historical performance and comparison
Is Abiomed undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ABMD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ABMD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ABMD is poor value based on its PE Ratio (99.5x) compared to the US Medical Equipment industry average (52.3x).
PE vs Market: ABMD is poor value based on its PE Ratio (99.5x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: ABMD is poor value based on its PEG Ratio (3.2x)
Price to Book Ratio
PB vs Industry: ABMD is overvalued based on its PB Ratio (11.7x) compared to the US Medical Equipment industry average (4.7x).
How is Abiomed forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABMD's forecast earnings growth (31% per year) is above the savings rate (2%).
Earnings vs Market: ABMD's earnings (31% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ABMD's revenue (15.4% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ABMD's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABMD's Return on Equity is forecast to be low in 3 years time (14.4%).
How has Abiomed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABMD has high quality earnings.
Growing Profit Margin: ABMD's current net profit margins (16.5%) are lower than last year (19.9%).
Past Earnings Growth Analysis
Earnings Trend: ABMD's earnings have grown significantly by 24.4% per year over the past 5 years.
Accelerating Growth: ABMD's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: ABMD had negative earnings growth (-2.7%) over the past year, making it difficult to compare to the Medical Equipment industry average (40.5%).
Return on Equity
High ROE: ABMD's Return on Equity (11.8%) is considered low.
How is Abiomed's financial position?
Financial Position Analysis
Short Term Liabilities: ABMD's short term assets ($729.9M) exceed its short term liabilities ($113.1M).
Long Term Liabilities: ABMD's short term assets ($729.9M) exceed its long term liabilities ($37.7M).
Debt to Equity History and Analysis
Debt Level: ABMD is debt free.
Reducing Debt: ABMD has no debt compared to 5 years ago when its debt to equity ratio was 0.05%.
Debt Coverage: ABMD has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ABMD has no debt, therefore coverage of interest payments is not a concern.
What is Abiomed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ABMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ABMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ABMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ABMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ABMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Minogue (54 yo)
Mr. Michael R. Minogue, also known as Mike, has been Chief Executive Officer and President of ABIOMED Europe GmbH since April 2004. Mr. Minogue has been Chief Executive Officer, President and Director of A...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD14.85M) is above average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: ABMD's management team is seasoned and experienced (5.3 years average tenure).
Experienced Board: ABMD's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abiomed, Inc.'s employee growth, exchange listings and data sources
- Name: Abiomed, Inc.
- Ticker: ABMD
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$15.360b
- Shares outstanding: 45.38m
- Website: https://www.abiomed.com
Number of Employees
- Abiomed, Inc.
- 22 Cherry Hill Drive
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 22:55|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.